Drug survival of Adalimumab and Infliximab in Hidradenitis S
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Biologics are often required for treatment of hidradenitis suppurativa (HS). A Study was conducted to assess the drug survival of anti-TNF biologics in a daily practice cohort of HS patients and to identify predictors for drug survival. A retrospective multicenter study was performed. Adult HS patients using biologics between 2008 and 2020 were included. Drug survival was analyzed using Kaplan Meier survival curves, predictors of survival using univariate Cox regression analysis.

Results:
--Overall drug survival of adalimumab with 104 patients at 12 and 24 months was 56.3% and 30.5%, mostly due to ineffectiveness.

--Older age and longer disease duration were associated with longer survival time.

--For infliximab (n=44), the overall drug survival was 58.3% and 48.6% at 12 and 24 months and was predominantly determined by infectiveness and side-effects.

--Surgery during treatment was associated with a longer survival time.

In conclusion, survival rates for adalimumab and infliximab at 12 months are similar and are largely determined by ineffectiveness. Age, duration of disease (adalimumab) and procedure (infliximab) are predictors of longer survival.

Source: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.19863?af=R
Like
Comment
Share